{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:51:23Z","timestamp":1790628683242,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81930111"],"award-info":[{"award-number":["81930111"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Community-acquired bacterial pneumonia (CABP) is an important health care concern in the worldwide, and is associated with significant morbidity, mortality, and health care expenditure. <jats:italic>Streptococcus pneumoniae<\/jats:italic> is the most frequent causative pathogen of CABP. Common treatment for hospitalized patients with CABP is empiric antibiotic therapy using \u03b2-lactams in combination with macrolides, respiratory fluoroquinolones, or tetracyclines. However, overuse of antibiotics has led to an increased incidence of drug-resistant S. <jats:italic>pneumoniae<\/jats:italic>, exacerbating the development of community-acquired drug-resistant bacterial pneumonia (CDBP) and providing a challenge for physicians to choose empirical antimicrobial therapy.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Traditional Chinese medicine (TCM) is widely used as a complementary treatment for CDBP. <jats:italic>Yinhuapinggan<\/jats:italic> granules (YHPG) is widely used in the adjuvant treatment of CDBP. Experimental studies and small sample clinical trials have shown that YHPG can effectively reduce the symptoms of CDBP. However, there is a lack of high-quality clinical evidence for the role of YHPG as a complementary drug in the treatment of CDBP. Here, we designed a randomized, double-blind, placebo-controlled clinical trial to explore the efficacy and safety of YHPG. A total of 240 participants will be randomly assigned to the YHPG or placebo group in a 1:1 ratio. YHPG and placebo will be added to standard treatment for 10\u00a0days, followed by 56\u00a0days of follow-up. The primary outcome is the cure rate of pneumonia, and the secondary outcomes includes conversion rate of severe pneumonia, lower respiratory tract bacterial clearance, lactic acid (LC) clearance rate, temperature, C-reactive protein (CRP), criticality score (SMART-COP score), acute physiological and chronic health assessment system (APACHEII score) and clinical endpoint events. Adverse events will be monitored throughout the trial. Data will be analyzed according to a pre-defined statistical analysis plan. This research will disclose the efficacy of YHPG in acquired drug-resistant pneumonia.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration<\/jats:bold>: <jats:ext-link>https:\/\/clinicaltrials.gov<\/jats:ext-link>, identifier ChiCTR2100047501<\/jats:p>","DOI":"10.3389\/fphar.2022.852604","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T06:01:57Z","timestamp":1656568917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Efficacy Protocol of Yinhuapinggan Granules: A Randomized, Double-Blind, Parallel, and Controlled Clinical Trial Program for the Intervention of Community-Acquired Drug-Resistant Bacterial Pneumonia as a Complementary Therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Jiaoli","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"R265","DOI":"10.1186\/cc13095","article-title":"Initial Use of One or Two Antibiotics for Critically Ill Patients with Community-Acquired Pneumonia: Impact on Survival and Bacterial Resistance","volume":"17","author":"Adrie","year":"2013","journal-title":"Crit. Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1093\/cid\/cis242","article-title":"Impact of an Antimicrobial Stewardship Intervention on Shortening the Duration of Therapy for Community-Acquired Pneumonia","volume":"54","author":"Avdic","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/crj.12674","article-title":"Diagnosis and Treatment of Community-Acquired Pneumonia in Adults: 2016 Clinical Practice Guidelines by the Chinese Thoracic Society, Chinese Medical Association","volume":"12","author":"Cao","year":"2018","journal-title":"Clin. Respir. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1086\/589754","article-title":"SMART-COP: a Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Community-Acquired Pneumonia","volume":"47","author":"Charles","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.1002\/anie.201506818","article-title":"Targeting Antibioticresistance","volume":"55","author":"Chellat","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B7","first-page":"229","article-title":"Research Progress on the Effect of Traditional Chinese Medicine Against Common Drug\u2010Resistant Bacteria and its Mechanism","volume":"35","author":"Cheng","year":"2019","journal-title":"J. Nanjing Univ. Traditional Chin. Med."},{"key":"B8","volume-title":"Draft of the Four General Rules of the 2020 Edition of the Chinese Pharmacopoeia","year":"2019"},{"key":"B9","first-page":"2039","article-title":"In Vitro Anti\u2010Influenza A H1N1 Virus Effect of Yinhuapinggan Granules","volume":"58","author":"Du","year":"2017","journal-title":"J. Traditional Chin. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11684-021-0856-3","article-title":"Clinical Factors Associated with Composition of Lung Microbiota and Important Taxa Predicting Clinical Prognosis in Patients with Severe Community-Acquired Pneumonia","volume":"24","author":"Du","year":"2021","journal-title":"Front. Med."},{"key":"B11","volume-title":"Guiding Principles for Clinical Research of New Traditional Chinese Medicine Drugs Trial","year":"2002"},{"key":"B12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2471\/BLT.11.088435","article-title":"The Who Policypackage to Combat Antimicrobial Resistance","volume":"8","author":"Emily","year":"2011","journal-title":"Bull World Health Organ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/MCP.0000000000000558","article-title":"Outpatient Management of Community-Acquired Pneumonia","volume":"25","author":"Froes","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1097\/MJT.0000000000000788","article-title":"Effect of \u03b2-Lactam Plus Macrolide versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia","volume":"27","author":"Gilbert","year":"2020","journal-title":"Am. J. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"ofw186","DOI":"10.1093\/ofid\/ofw186","article-title":"Effects of a Syndrome-specific Antibiotic Stewardship Intervention for Inpatient Community-Acquired Pneumonia","volume":"3","author":"Haas","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.4268\/cjcmm20160509","article-title":"Research Progress on Antibacterial Resistance of Traditional Chinese Medicine","volume":"4","author":"Han","year":"2016","journal-title":"Chin. J. Chin. Materia Medica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3760\/cma.j.issn.2095-4352.2018.05.019","article-title":"Research Progress on the Epidemiology and Prognosis of Sepsis","volume":"30","author":"He","year":"2018","journal-title":"Chin. J. Crit. Care Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.16718\/j.1009-7708.2018.03.001","article-title":"Surveillance of Bacterial Drug Resistance in China by CHINET in 2017","volume":"18","author":"Hu","year":"2018","journal-title":"Chin. J. Infect. Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"E3463","DOI":"10.1073\/pnas.1717295115","article-title":"Global Increase and Geographic Convergence in Antibiotic Consumption between 2000 and 2015","volume":"115","author":"Klein","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"Apache II: a Severity of Disease Classification System","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit. Care Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/QCO.0000000000000526","article-title":"New Antibiotics for Community-Acquired Pneumonia","volume":"32","author":"Kollef","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fcimb.2017.00483","article-title":"Antimicrobial Resistance of Hypervirulent Klebsiella pneumoniae: Epidemiology, Hypervirulence-Associated Determinants, and Resistance Mechanisms","volume":"7","author":"Lee","year":"2017","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1017\/ice.2016.165","article-title":"Sustained Impact of an Antibiotic Stewardship Intervention for Community-Acquired Pneumonia","volume":"37","author":"Li","year":"2016","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14728214.2019.1685494","article-title":"Emerging Antibiotics for Community-Acquired Pneumonia","volume":"24","author":"Liapikou","year":"2019","journal-title":"Erratum Expert Opin Emerg Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/bcpt.13205","article-title":"Short-course vs Long-Course Antibiotic Treatment for Community-Acquired Pneumonia: A Literature Review","volume":"124","author":"M\u00f8ller Gundersen","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"107663","DOI":"10.1016\/j.pharmthera.2020.107663","article-title":"Updates on Community Acquired Pneumonia Management in the ICU","volume":"217","author":"Nair","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.4268\/cjcmm20151926","article-title":"In Vivo Anti\u2010Influenza A H1N1 Influenza Virus Effect of Yinhua Pinggan Granules","volume":"40","author":"Peng","year":"2015","journal-title":"Chin. J. Chin. Materia Medica"},{"key":"B29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.intimp.2015.11.029","article-title":"Protective Effects of Yinhuapinggan Granule on Mice with Influenza Viral Pneumonia","volume":"30","author":"Peng","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11418-015-0939-z","article-title":"Antiviral Effects of Yinhuapinggan Granule against Influenza Virus Infection in the ICR Mice Model","volume":"70","author":"Peng","year":"2016","journal-title":"J. Nat. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3760\/cma.j.issn.1001-0939.2016.04.005","article-title":"Chinese Society of Respiratory Medicine. Guidelines for the Diagnosis and Treatment of Adult Community-Acquired Pneumonia in China (2016 Edition)","volume":"39","author":"Qu","year":"2016","journal-title":"Chinese J. Tubercul. Respir. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.12788\/jhm.2905","article-title":"Shorter versus Longer Courses of Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis","volume":"13","author":"Royer","year":"2018","journal-title":"J. Hosp. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"B34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/1120009X.2020.1807231","article-title":"Community-acquired Pneumonia: Aetiology, Antibiotic Resistance and Prospects of Phage Therapy","volume":"32","author":"Sheam","year":"2020","journal-title":"J. Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"210","DOI":"10.7326\/M19-1509","article-title":"Duration of Antibiotic Therapy: Shorter Is Better","volume":"171","author":"Spellberg","year":"2019","journal-title":"Ann. Intern Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination Therapy for Treatment of Infections with Gram-Negative Bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00134-019-05519-y","article-title":"Challenges in Severe Community-Acquired Pneumonia: a Point-Of-View Review","volume":"45","author":"Torres","year":"2019","journal-title":"Intensive Care Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1001\/jamainternmed.2016.3633","article-title":"Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial","volume":"176","author":"Uranga","year":"2016","journal-title":"JAMA Intern Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.idc.2016.02.004","article-title":"Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned","volume":"30","author":"van Duin","year":"2016","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B40","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.idc.2020.08.002","article-title":"Multidrug-Resistant Bacteria in the Community: An Update","volume":"34","author":"van Duin","year":"2020","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.7326\/M18-3640","article-title":"Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized with Pneumonia: A Multihospital Cohort Study","volume":"171","author":"Vaughn","year":"2019","journal-title":"Ann. Intern Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3390\/molecules25225319","article-title":"Estimation of Sample Size in Clinical Studies: (1) Clinical Trials","volume":"48","author":"Wan","year":"2017","journal-title":"J. Tradit. Chin. Med."},{"key":"B43","first-page":"1469","article-title":"Diagnosis and Curative Effect Evaluation Criteria for the Syndrome of Exogenous Febrile Disease and Stagnation of Lung Health (Trial Implementation)","volume":"12","author":"Wan","year":"2017","journal-title":"World J. Integr. Traditional Chin. West. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"571106","DOI":"10.3389\/fphar.2020.571106","article-title":"Effects of Guanxinshutong Capsules as Complementary Treatment in Patients with Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"625785","DOI":"10.3389\/fphar.2021.625785","article-title":"Design and Methodology of a Multicenter Randomized Clinical Trial to Evaluate the Efficacy of Tongmai Jiangtang Capsules in Type 2 Diabetic Coronary Heart Disease Patients","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.clinthera.2019.01.007","article-title":"Outpatient Antimicrobial Stewardship: Targets for Community-Acquired Pneumonia","volume":"41","author":"Wattengel","year":"2019","journal-title":"Clin. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12890-019-0944-1","article-title":"Severe Community-Acquired Pneumonia in General Medical Wards: Outcomes and Impact of Initial Antibiotic Selection","volume":"19","author":"Wongsurakiat","year":"2019","journal-title":"BMC Pulm. Med."}],"updated-by":[{"DOI":"10.3389\/fphar.2022.986640","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.852604\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T11:28:59Z","timestamp":1660562939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.852604\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":46,"alternative-id":["10.3389\/fphar.2022.852604"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.852604","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fphar.2022.986640","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"article-number":"852604"}}